Johnson & Johnson (NYSE:JNJ) Stock Falls 1.2% – What’s Next?

Johnson & Johnson (NYSE:JNJ)’s share price traded down 1.2% during trading on Monday. The company traded as low as $252.51 and last traded at $252.8960. Approximately 9,016,570 shares were traded during mid-day trading, an increase of 13% from the average daily volume of 8,001,250 shares. The stock had previously closed at $256.03.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JNJ. Scotiabank reiterated an “outperform” rating and issued a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, September 22nd. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Finally, Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $276.09.

Johnson & Johnson Stock Performance

The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average is $266.37 and its 200 day moving average is $248.40. The stock has a market capitalization of $609.45 billion, a price-to-earnings ratio of 29.30, a PEG ratio of 2.52 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts predict that Johnson & Johnson will post 11.54 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

Insider Buying and Selling

In related news, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Baker Tilly Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 4.7% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 10,423 shares of the company’s stock worth $2,759,000 after purchasing an additional 469 shares during the period. Ferguson Wellman Capital Management Inc. grew its position in shares of Johnson & Johnson by 41.0% in the third quarter. Ferguson Wellman Capital Management Inc. now owns 666,675 shares of the company’s stock valued at $176,495,000 after purchasing an additional 193,905 shares during the period. Adelphi Trust Co grew its position in shares of Johnson & Johnson by 5.1% in the third quarter. Adelphi Trust Co now owns 1,950 shares of the company’s stock valued at $516,000 after purchasing an additional 95 shares during the period. Eastern Bank increased its stake in Johnson & Johnson by 105.9% in the third quarter. Eastern Bank now owns 299,306 shares of the company’s stock valued at $79,238,000 after purchasing an additional 153,938 shares during the last quarter. Finally, Polaris Financial Partners purchased a new position in Johnson & Johnson during the third quarter worth about $56,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.